By 
December 28, 2022 (Investorideas.com Newswire) The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.
You may also like
Sign Up Now And Start Your Journey To Success! Get your Stock Reports...
Please Enter Your E-mail Address Below:
By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!
Comments